Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dalyna, Quach"'
Autor:
Dalyna, Quach, Boshen, Jiao, Anirban, Basu, M A, Bender, Jane, Hankins, Scott, Ramsey, Beth, Devine
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:891-911
Sickle cell disease (SCD) is a rare genetic disease with limited therapeutic options. Gene-based therapies are being investigated in clinical trials to evaluate their curative potential. The expected life-long benefits of one-time administration of g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afeb079b319fe71d4b5d390fd0693bad
https://doi.org/10.1080/14737167.2022.2060823
https://doi.org/10.1080/14737167.2022.2060823
Autor:
Ilsa I. Rovira, Anirban Basu, Dalyna Quach, Joshua A. Roth, Traci Clemons, M Bender, Beth Devine, Scott D. Ramsey, Boshen Jiao
Publikováno v:
PharmacoEconomics. 39:1225-1241
Novel interventions for sickle cell disease (SCD) bring hope to patients, yet concern about the associated economic costs exists. Cost-effectiveness analysis (CEA) uses standardized methods, with robust underpinnings in health economics, to estimate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a601a924a948ee262912b3a0ef6fd2a
https://doi.org/10.1007/s40273-021-01072-z
https://doi.org/10.1007/s40273-021-01072-z
Autor:
Boshen, Jiao, Anirban, Basu, Joshua, Roth, M, Bender, Ilsa, Rovira, Traci, Clemons, Dalyna, Quach, Scott, Ramsey, Beth, Devine
Publikováno v:
PharmacoEconomics. 39(11)
Novel interventions for sickle cell disease (SCD) bring hope to patients, yet concern about the associated economic costs exists. Cost-effectiveness analysis (CEA) uses standardized methods, with robust underpinnings in health economics, to estimate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4272dee267ea1577a90e5efc57719ac8
https://pubmed.ncbi.nlm.nih.gov/34368937
https://pubmed.ncbi.nlm.nih.gov/34368937
Autor:
Beth Devine, Boshen Jiao, Scott D. Ramsey, Dalyna Quach, M.A. Bender, Anirban Basu, Joshua A. Roth
Publikováno v:
Value Health
Objectives Sickle cell disease (SCD) is a complex, chronic condition that impairs health-related quality of life of affected individuals and their caregivers. As curative therapies emerge, comprehensive cost-effectiveness models will inform their val
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fce98f6729869d7d6b169c861c1a615
https://pubmed.ncbi.nlm.nih.gov/35094801
https://pubmed.ncbi.nlm.nih.gov/35094801